If genetic testing for HαT is not feasible, it may be reasonable to follow tryptase over time after exclusion of alternative causes such as chronic kidney disease, myeloproliferative disorders and CMCD. This evidence concerns the gene TMPRSS11D and myeloproliferative disorder.